ABOUT THE K36-MMSET-001 STUDY

BACKGROUND

The K36-MMSET-001 study has been designed to assess the effectiveness and safety of KTX-1001, an investigational* drug for patients with multiple myeloma who have limited treatment options. The safest and most effective dose of KTX-1001 will also be identified during the study. **KTX-1001 is a potentially new drug that blocks a protein that is overexpressed in multiple myeloma.**

**"Investigational" means the study drug is available for use in clinical research but not yet available for the treatment of Multiple Myeloma.*

ELIGIBILITY

- ✓ At least 18 years of age
- ✓ Have confirmed diagnosis of relapsed or refractory multiple myeloma
- ✓ Received at least 2 prior treatments for your multiple myeloma

STUDY DESIGN

The K36-MMSET-001 study has two parts: you will be enrolled into one of the two parts.

DOSE ESCALATION PART A

Participants will receive KTX-1001 at dose levels based on safety information collected during the study. The dose will increase as more participants receive KTX-1001 and more is learned about how KTX-1001 affects the body in order to choose the most effective and tolerable dose.

DOSE EXPANSION PART B

Participants will receive the KTX-1001 dose selected in Part A combined with standard-of-care medications.

CONTACT US

1 MAIN STREET, 14FL, CAMBRIDGE, MA 02142

WWW.K36TX.COM

INFO@K36TX.COM

WWW.LINKEDIN.COM/COMPANY/K36-THERAPEUTICS

WWW.INSTAGRAM.COM/K36TX

WWW.TWITTER.COM/K36TX

WWW.FACEBOOK.COM/K36TX

FAMILY BROCHURE V2 - 12AUG24

DO YOU OR YOUR LOVED ONE HAVE **MULTIPLE MYELOMA THAT IS NO LONGER RESPONDING TO TREATMENT?**

We have a clinical trial for patients who are looking for potential new treatment options. If you have relapsed or refractory multiple myeloma you may want to consider participating in the K36-MMSET-001 study.

k36 therapeutics

PARTICIPATING IN THE STUDY

WHAT ARE CLINICAL STUDIES?

Without clinical studies and the volunteers who participate in these studies no potential new treatments could be developed. Clinical studies:

- **Find new ways** to prevent, detect or treat conditions, including multiple myeloma.
- **Provide important information** about the safety and effectiveness of potential new medications.
- **Follow standards and are closely regulated**. Every study is reviewed and monitored carefully to make sure that the rights of participants are protected, no unnecessary risks are involved and that the study answers important medical questions.

THE GOAL OF PHASE I STUDIES IS TO FIND OUT:

Phase I clinical studies include a small number of participants with the condition under study.

- ✓ How well the study drug works
- ✓ Potential side effects of the study drug
- ✓ A tolerable dose for the study drug
- ✓ If the study drug will work for your condition

WHAT WILL HAPPEN IF I PARTICIPATE?

If you are interested in the study, you will:

- **Be given an informed consent form** to read and sign. This form will provide you with all study details, including potential risks and benefits, and you will be given a chance to ask any questions you might have before signing the consent form.
- **Complete the screening period** where study doctors will ask you a number of medical questions and you will have health tests performed to determine if you qualify for this study.

If during the study you change your mind, you are free to leave at any point. During the study, the study drug will be provided to you at no charge.

WHAT HAPPENS AT STUDY VISITS?

At the study visits, you will:

- **Have health checks** including, temperature, blood pressure, pulse, and breathing rate, blood/urine tests, bone marrow samples, and imaging to assess your disease.
- **Talk with your study doctor or study team** and they will answer questions you may have.
- **Receive the study drug**, based on part of the study and dose level that your study doctor will provide.
- **Be given a study diary** and instructions on how to complete the diary.
- Take **KTX-1001 by mouth** every day.

Screening Period

Up to 28 Days

Informed consent followed by screening tests and procedures to find out if you qualify to participate in the study

Participant qualifies for the study

Treatment Period

4-week Treatment Cycles

After first 2 months (2 cycles), visits are monthly

End of Treatment Visit

Post Treatment Visit

Myeloma Follow up

Dose Expansion Part B Only